Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial of Adagrasib (MRTX849) + Pembrolizumab in KRAS G12C-Mutated Advanced NSCLC
2020-003101-58Phase 2Active
- Sponsor
- Mirati Therapeutics
- Start
- May 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of adagrasib and pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Mirati Therapeutics. Primary endpoint: Objective Response Rate (ORR). Started May 2021; status: active.
02
Drugs
adagrasibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-003101-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003101-58.